[Previous Months][Date Index][Thread Index][Join - Register][Login]   Help@Insulin-Pumpers.org
  [Message Prev][Message Next][Thread Prev][Thread Next]   for subscribe/unsubscribe assistance

[IP] SpectRx, Inc. Granted Key Insulin Delivery Patch Patent

	NORCROSS, GA (October 21, 2003) -- SpectRx, Inc. (OTCBB: 
SPRX) today announced it was granted an important patent for its 
SimpleChoice(r) patch insulin delivery technology.  U.S. patent 
number 6,629,949 is the first of what is expected to be a series of 
patents covering the infusion patch and insulin infusion micropump 
technology.  The first patch product is an insulin pump infusion set, 
and is expected to be available later this year.  The annual U.S. 
insulin pump infusion set market is approximately $270 million.

	"We believe that the patch is a significant innovation in 
insulin delivery, and because of its unique design, will energize the 
insulin pump market and may cause more people to turn to insulin pump 
therapy to control their diabetes," said Mark A. Samuels, SpectRx, 
Inc. chairman and CEO.  "The award of this initial patent is also 
important because it sets the stage for partnerships and licensing 

	The FDA-cleared patch is designed for use with most insulin 
pumps on the market today.  The patch delivers insulin through five 
microneedles that are much smaller than ordinary insulin pump 
infusion needles.  The reduced depth of penetration is designed to 
improve comfort and the overall pump experience.
for HELP or to subscribe/unsubscribe, contact: